These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2399526

  • 21. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A, Sasaki Y, Odawara A, Morita T.
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [Abstract] [Full Text] [Related]

  • 22. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A, Kawakage M, Shirakura S, Higo K, Kubo K, Ohshima E, Obase H.
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [Abstract] [Full Text] [Related]

  • 23. Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.
    Mehta JL.
    Am J Cardiol; 1985 Jan 25; 55(3):158B-164B. PubMed ID: 2982252
    [Abstract] [Full Text] [Related]

  • 24. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S, Nakahata N, Ohizumi Y.
    Br J Pharmacol; 1996 Mar 25; 117(6):1095-104. PubMed ID: 8882602
    [Abstract] [Full Text] [Related]

  • 25. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar 25; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

  • 26. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
    Hanasaki K, Arita H.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3923-9. PubMed ID: 2973322
    [Abstract] [Full Text] [Related]

  • 27. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.
    Han P, Boatwright C, Ardlie NG.
    Thromb Haemost; 1983 Aug 30; 50(2):513-7. PubMed ID: 6314581
    [Abstract] [Full Text] [Related]

  • 28. Effects of calcium channel blockers on in vitro platelet function in whole blood using single platelet counting.
    Walley TJ, Woods KL, Barnett DB.
    Thromb Haemost; 1989 Feb 28; 61(1):137-9. PubMed ID: 2749586
    [Abstract] [Full Text] [Related]

  • 29. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH.
    Br J Pharmacol; 1985 Mar 28; 84(3):595-607. PubMed ID: 2580580
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effects of verapamil and diltiazem on human platelet function.
    Addonizio VP, Fisher CA, Strauss JF, Wachtfogel YT, Colman RW, Josephson ME.
    Am J Physiol; 1986 Mar 28; 250(3 Pt 2):H366-71. PubMed ID: 3006516
    [Abstract] [Full Text] [Related]

  • 32. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan 28; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological profile of G619, a new platelet aggregation inhibitor.
    Yue TL, Smith EF, Ohlstein EH, Sulpizio A, Slivjak MJ, Rabinovici R, Sellers TS, Lynch KM, Poyser R, Feuerstein G.
    Thromb Res; 1992 May 15; 66(4):331-47. PubMed ID: 1412200
    [Abstract] [Full Text] [Related]

  • 34. Variable potency of nitrergic-nitrovasodilator relaxations of the mouse anococcygeus against different forms of induced tone.
    Gibson A, McFadzean I, Tucker JF, Wayman C.
    Br J Pharmacol; 1994 Dec 15; 113(4):1494-500. PubMed ID: 7889307
    [Abstract] [Full Text] [Related]

  • 35. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor.
    Sato T, Hashizume T, Nakao K, Akiba S, Fujii T.
    Biochim Biophys Acta; 1989 Aug 18; 992(2):168-73. PubMed ID: 2503041
    [Abstract] [Full Text] [Related]

  • 36. Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy.
    Manninen A.
    Pharmacol Toxicol; 1996 Jun 18; 78(6):387-91. PubMed ID: 8829198
    [Abstract] [Full Text] [Related]

  • 37. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine.
    Alarayyed NA, Cooper MB, Prichard BN, Betteridge DJ, Smith CC.
    Br J Clin Pharmacol; 1997 Apr 18; 43(4):415-20. PubMed ID: 9146854
    [Abstract] [Full Text] [Related]

  • 38. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
    Jones CR, Pasanisi F, Elliott HL, Reid JL.
    Br J Clin Pharmacol; 1985 Sep 18; 20(3):191-6. PubMed ID: 2994701
    [Abstract] [Full Text] [Related]

  • 39. Cinnamophilin, a novel thromboxane A2 receptor antagonist, isolated from Cinnamomum philippinense.
    Yu SM, Ko FN, Wu TS, Lee JY, Teng CM.
    Eur J Pharmacol; 1994 Apr 11; 256(1):85-91. PubMed ID: 8026563
    [Abstract] [Full Text] [Related]

  • 40. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation.
    Dehpour AR, Samadian T, Akhavan MM, Meysamee F, Delfan A.
    Gen Pharmacol; 1995 Oct 11; 26(6):1295-9. PubMed ID: 7590122
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.